Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.
Location: Netherlands, Gelderland, Nijmegen
Member count: 11-50
Total raised: $47.289596M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | Meneldor | meneldor.n... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 08.09.2021 | - | $47.289596... | - | prnewswire... |
Mentions in press and media 4
| Date | Title | Description | Category | Author | Source |
| 08.09.2021 | Xenikos Se... | - | Press Rele... | - | medicxi.co... |
| 08.09.2021 | Xenikos Se... | NIJMEGEN, the Netherlands, S... | - | - | prnewswire... |
| 13.12.2018 | Dutch tech... | The Netherlands is one of the ... | bitfury D... | Editorial ... | siliconcan... |
| 15.05.2018 | Medicxi, R... | Bringing Medicxi and RA Capi... | Financing | Amber Tong | endpts.com... |